Results from a randomized, controlled Investigational Device Exemption trial of Vertiflex’s Superion® Indirect Decompression System in patients with lumbar spinal stenosis (LSS) showed an 85% decrease in the proportion of patients using opioids, five years after treatment with the device. Primary analysis included all 190 randomized patients receiving Superion.
Superion received FDA Premarket Approval in 2015 for the treatment of LSS. The device prevents compression of spinal nerves and vasculature while walking and standing, when symptoms most commonly manifest, and does not require the removal of any bone or tissue to implant.
Results from a randomized, controlled Investigational Device Exemption trial of Vertiflex's Superion® Indirect Decompression System in patients with lumbar spinal stenosis (LSS) showed an 85% decrease in the proportion of patients using opioids, five years after treatment with the device. Primary analysis included all 190 randomized patients...
Results from a randomized, controlled Investigational Device Exemption trial of Vertiflex’s Superion® Indirect Decompression System in patients with lumbar spinal stenosis (LSS) showed an 85% decrease in the proportion of patients using opioids, five years after treatment with the device. Primary analysis included all 190 randomized patients receiving Superion.
Superion received FDA Premarket Approval in 2015 for the treatment of LSS. The device prevents compression of spinal nerves and vasculature while walking and standing, when symptoms most commonly manifest, and does not require the removal of any bone or tissue to implant.
Copy to clipboard 
